Apr 25, 2022

Organizational and Personnel Changes

TOKYO, April 25, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the following organizational and personnel changes, effective July 1, 2022.

[Details of Organizational Changes]

1. Reorganization of Pharmaceutical Technology Div.

Pharmaceutical Technology Div. currently has two functions: the R&D function for pharmaceutical technology (PT) including technical research, and the manufacturing function to supply high-quality investigational drugs and products in a stable and efficient manner, in cooperation with a manufacturing subsidiary Chugai Pharma Manufacturing Co., Ltd. (CPMC). Two separate divisions will be in place to further enhance these functions which play a key role in realizing TOP I 2030.

  • Pharmaceutical Technology Div. will be divided into Pharmaceutical Technology Div., which is centered on the PT R&D function, and Manufacturing Technology Div., which is centered on the manufacturing function. Related departments will be also reorganized.
  • Pharmaceutical Technology Div. will include PT Planning & Coordination Dept., CMC Regulatory Affairs Dept., API Process Development Dept., Formulation Development Dept., and Analytical Development Dept. Manufacturing Technology Div. will consist of Supply Chain Management Dept., Quality Management Dept. and CPMC.

[Structure after reorganization]

Organizational chart of PT Div. after reorganization

2. Reorganization of Marketing & Sales Div.

In order to further strengthen the expertise and to concentrate on growth and new areas, the region-based sales organization will be changed into a disease area-based system focusing on the two diseases areas of oncology and specialty diseases, considering the changes in the healthcare industry and the Company’s portfolio of products and projects under development. The 36 sales branches in Japan will also be reorganized into 33 branches. Back office operations in regional management offices will be consolidated and centralized to enable efficient and fast collaboration with related organizations.

  • Hokkaido & Tohoku Regional Management Office will be renamed Kita-Nihon Regional Management Office
  • Oncology Marketing & Sales Promotion Dept. and Primary Marketing & Sales Promotion Dept. will be renamed Oncology Marketing Dept. and Specialty Marketing Dept., respectively.

3. Other renames

Considering the portfolio of products and projects under development, ”Primary” used in the names of organizations will be replaced with “Specialty.”

New NameCurrent Name
Specialty Lifecycle Management Dept.
Project & Lifecycle Management Unit
Primary Lifecycle Management Dept.
Project & Lifecycle Management Unit
Specialty Clinical Development Dept.
Clinical Development Div.
Primary Clinical Development Dept.
Clinical Development Div.

[Details of Personnel Changes]

Vice President

NameNew ResponsibilitiesCurrent Responsibilities
Shinya Takuma Vice President
Head of Manufacturing Technology Div. and President of Chugai Pharma Manufacturing Co., Ltd.
Vice President
Head of Pharmaceutical Technology Div. and President of Chugai Pharma Manufacturing Co., Ltd.

Please see the PDF file about other personnel changes.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top